source
- Amylyx reports promising GLP-1 blocker results while Summit faces survival setbacks and Definium shows anxiety therapy benefitAmylyx said its investigational GLP-1 blocker avexitide cut the combined rate of level 2 and level 3 hypoglycemic events by about 55% in patients with post‑bariatric hypoglycemia, beating analyst e…
- LabCentral partners with Hong Kong Science and Technology Parks to link biotech founders across US and ChinaLabCentral, a Massachusetts biotech accelerator, signed a memorandum of understanding with Hong Kong Science and Technology Parks Corporation (HKSTP) in June at the BIO International Convention. T…